.S. Equity News: ImClone Systems Showcases Extensive Research and Development Program at the AACR Annual Meeting
Apr 23, 2007 (M2 PRESSWIRE via COMTEX) -- City of Industry, CA - Biotechnology
industry alert provided by U.S. Equity News. IgG1 monoclonal antibodies
developed by ImClone Systems Incorporated (NASDAQ: IMCL) were the focus of 44
total presentations at the recently concluded 98th Annual Meeting of the
American Association for Cancer Research (AACR), including seven oral
presentations and 37 posters. Important ERBITUX (cetuximab) clinical data were
the focus of two back-to-back oral presentations leading off the "Breakthroughs
in Clinical Research" Plenary Session on April 16, 2007, which highlights the
most important clinical studies presented at this prestigious meeting.
